资源描述：
《《共同促进结直肠癌精准治疗》培训课件》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。
1、共同促进结直肠癌精准治疗李进教授复旦大学肿瘤医院来自全国20多个个省市的100多名同道济济一堂，交流ASCO新进展3RAS是目前mCRC唯一确定的生物标志物，西妥昔单抗是肠癌唯一符合精准治疗的药物HR=0.69(0.54–0.88)p=0.0024Δ=8.2monthsHR=0.796(0.67–0.95)p=0.0093HR=0.878(0.77–1.00)p=0.0419Δ=3.5monthsΔ=1.3months1.VanCutsemE,etal.JClinOncol2011;29:2011–2019; 2.VanCutsemE,etal.JClinOncol201
2、5;33:692–700; 3.DouillardJ-Y,etal.NEnglJMed2013;369:1023–1034;4.ErbituxSmPCJune2014;5.VectibixSmPCFebruary2015.FigureadaptedfromdatafromVanCutsemE,etal.2CetuximabandpanitumumabareapprovedinpatientswithRASwtmCRC.4,5CetuximabandpanitumumabarenotindicatedforthetreatmentofpatientswithmCRCwhos
3、etumorshaveRASmutationsorforwhomRAStumorstatusisunknown.4,5Cetuximab+FOLFIRI(n=178)FOLFIRI(n=189)0.00.20.40.60.81.0Months5442481861224303628.420.20Months54424823.520.00.00.20.40.60.81.0180612243036Months5442480.00.20.40.60.81.0180612243036OSestimate19.918.6Cetuximab+FOLFIRI(n=599)FOLFIRI(
4、n=599)Cetuximab+FOLFIRI(n=316)FOLFIRI(n=350)RASwt2KRASexon2wt1ITT(unselected)1通过RAS检测筛选最优势人群，使患者获益最大化4精准制定治疗方案，最大化患者生存精准制定治疗方案，最大化患者生存肿瘤生物学特征患者特征治疗相关疗效，安全性等精准治疗的未来发展方向更加个体化新药研发不同通路的靶向联用免疫治疗动态监测分子分型更好的识别和定义病人的分组未来现状：mCRCRASMMR/MSIBRAF6第52届ASCO年会>35000人参会主题：汇聚智慧7TitleofPresentation
5、DD.MM.YY
6、YYASCO年会爱必妥主要数据SomeMerckdatahighlights…Thehighlightisavelumab(anti-PD-L1)with14abstractsacceptedforpresentation.Includes2oralpresentations,3posterdiscussionsand9postersAndforErbitux,11abstractsfromISTs(oranindependentstudy)wereaccepted:Includes3oralpresentations,2posterdiscussion,and5post
7、ersAcronymAbstractTitleAuthorsNotificationAbstract#FIREIIIMiR-31-3pisapredictivebiomarkerofcetuximabefficacyeffectinmetastaticcolorectalcancer(mCRC)patientsenrolledinFIRE-3studyLaurent-PuigP,GrisoniM-L,HeinemannV,BonnetainF,FontaineK,VazartC,DecaulneV,RousseauF,LiebaertF,PathologistS,Jung
8、A,ThiébautR,StintzingSPosterdiscussionSaturday,June4,20161:15-2:30PM3516FIREIIITime-courseevaluationofsurvivalandtreatmentinFIRE-3trial(AIOKRK0306)Modestetal.Postersession:Gastrointestinal(Colorectal)CancerSaturday,June4,20168:00-11:30AM3528ACCORD21FOLFIRINOXcombine
